PRESS RELEASE published on 02/04/2026 at 15:03, 7 months 26 days ago Form 8.3 - The Vanguard Group, Inc.: JTC plc The Vanguard Group, Inc. discloses a 5.07% stake in JTC plc as of 03 February 2026. Purchase of 353 securities at 12.94 GBP per unit The Vanguard Group Financial Disclosure Stake Disclosure Securities Purchase JTC Plc
PRESS RELEASE published on 02/04/2026 at 15:02, 7 months 26 days ago Form 8.3 - The Vanguard Group, Inc.: Avadel Pharmaceuticals plc The Vanguard Group, Inc. discloses a 5.94% stake in Avadel Pharmaceuticals plc as of 03-Feb-2026. Details on securities owned and recent transactions provided Securities Transactions The Vanguard Group, Inc. Stake Disclosure Avadel Pharmaceuticals Plc
BRIEF published on 02/03/2026 at 15:47, 7 months 27 days ago The Vanguard Group Discloses Stake in Dauch Corporation Takeover Code Securities Disclosure Vanguard Group Dowlais Group Dauch Corporation
BRIEF published on 02/03/2026 at 15:47, 7 months 27 days ago Le groupe Vanguard révèle sa participation dans Dauch Corporation Groupe Vanguard Code De Prise De Contrôle Information Sur Les Valeurs Mobilières Groupe Dowlais Dauch Corporation
BRIEF published on 02/03/2026 at 15:47, 7 months 27 days ago The Vanguard Group, Inc. Discloses Position in JTC plc Form 8.3 Disclosure Takeover Code Vanguard Group JTC Plc
BRIEF published on 02/03/2026 at 15:47, 7 months 27 days ago Le groupe Vanguard révèle sa participation dans JTC plc Groupe Vanguard Code De Prise De Contrôle Divulgation Formulaire 8.3 JTC Plc
BRIEF published on 02/03/2026 at 15:46, 7 months 27 days ago Vanguard Group Discloses Position in Glencore and Rio Tinto Form 8.3 Vanguard Glencore Rio Tinto Securities Position
BRIEF published on 02/03/2026 at 15:46, 7 months 27 days ago Vanguard Group révèle sa position dans Glencore et Rio Tinto Formulaire 8.3 Avant-garde Glencore Rio Tinto Position Sur Titres
BRIEF published on 02/03/2026 at 15:45, 7 months 27 days ago The Vanguard Group Discloses New Position in Avadel Pharmaceuticals Form 8.3 Irish Takeover Panel Vanguard Group Shareholding Avadel Pharmaceuticals
BRIEF published on 02/03/2026 at 15:45, 7 months 27 days ago Le groupe Vanguard révèle une nouvelle participation dans Avadel Pharmaceuticals Actionnariat Groupe Vanguard Formulaire 8.3 Avadel Pharmaceuticals Panel Irlandais Des OPA
Published on 09/30/2026 at 15:50, 3 hours 37 minutes ago Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans
Published on 09/30/2026 at 14:37, 4 hours 50 minutes ago NuRAN Leverages Starlink Backhaul to Drive Higher Revenue Per Rural Site
Published on 09/30/2026 at 14:31, 4 hours 56 minutes ago First Breach Expands Ammunition Manufacturing Operations to Seven Days a Week
Published on 09/30/2026 at 14:07, 5 hours 20 minutes ago Worksport COR Energy System Now Available Through Amazon
Published on 09/30/2026 at 13:30, 5 hours 57 minutes ago Nextech3D.ai Engages MZ Group to Lead Strategic Investor Relations Program
Published on 09/30/2026 at 18:39, 47 minutes ago Advanced Blockchain AG Publishes 2026 Half-Year Report and Advances ABAG 2.0 Strategy
Published on 09/30/2026 at 18:26, 1 hour 1 minute ago Kaufman & Broad SA: RESULTATS DES NEUF PREMIERS MOIS DE 2026
Published on 09/30/2026 at 18:26, 1 hour 1 minute ago Kaufman & Broad SA: RESULTS FOR THE FIRST NINE MONTHS OF 2026
Published on 09/30/2026 at 18:13, 1 hour 13 minutes ago Freelance.com: Mise à disposition du document d'enregistrement universel 2025
Published on 09/30/2026 at 18:12, 1 hour 15 minutes ago BOOSTER Precision Components Holding announces prolongation of standstill agreement with Ad-hoc Group
Published on 09/30/2026 at 18:18, 1 hour 9 minutes ago Nombre total de droits de vote et d'actions composant le capital social
Published on 09/30/2026 at 18:15, 1 hour 12 minutes ago The Belgian State and ENGIE Group have agreed to extend the target date for concluding the Heads of Terms until 4 november 2026
Published on 09/30/2026 at 18:15, 1 hour 12 minutes ago L’État belge et le groupe ENGIE ont convenu de reporter au 4 novembre 2026 la date cible pour la conclusion des Heads of Terms
